Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in March Investor Conferences

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Enchant whitepaper: Breaking the data wall between lab and clinic

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

Presentation at Bio IT World Annual Conference

Panel and fireside chat at the HC Wainwright AI-Based Drug Discovery and Development Conference

Presentation at the KeyBanc Capital Markets Healthcare Forum

Presentation at the Pharmaceutical and Bioscience Society

Presentation at the AI in Drug Discovery Conference

Fireside chat at the Morgan Stanley Technology, Media and Telecom Conference

Panel presentation at the Biocom California Annual Partnering and Investor Conference

Presentation at the 43rd Annual JP Morgan Healthcare Conference

Podcast: Revolutionizing Drug Discovery with AI